Arash Alizadeh, Age 50328 Greenfield Ave, San Mateo, CA 94403

Arash Alizadeh Phones & Addresses

328 Greenfield Ave, San Mateo, CA 94403 (650) 571-1418

3353 Alma St, Palo Alto, CA 94306

Stanford, CA

Santa Ana, CA

Fountain Vly, CA

Work

Company: Stanford Hospital and Clinics Address: 300 Pasteur Drive, Stanford, CA 94305

Education

School / High School: Stanford University 1999

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Hematology, 2009

Mentions for Arash Alizadeh

Work History and Career Records

Medicine Doctors

Arash Alizadeh Photo 1

Dr. Arash A Alizadeh, Palo Alto CA - MD (Doctor of Medicine)

Specialties:
Hematology
Medical Oncology
Oncology
Address:
875 Blake Wilbur Dr, Palo Alto, CA 94304
(650) 498-6000 (Phone) (650) 724-5203 (Fax)
269 Campus Dr Suite 1145, Stanford, CA 94305
(650) 725-6423 (Phone) (650) 736-2282 (Fax)
Certifications:
Hematology, 2009
Internal Medicine, 2008
Medical Oncology, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
875 Blake Wilbur Dr, Palo Alto, CA 94304
269 Campus Dr Suite 1145, Stanford, CA 94305
Stanford Hospital and Clinics
300 Pasteur Drive, Stanford, CA 94305
Education:
Medical School
Stanford University
Graduated: 1999

Arash A. Alizadeh

Specialties:
Hematology/Oncology
Work:
Stanford Health Cancer Center Lymphoma Program
875 Blake Wilbur Dr, Palo Alto, CA 94304
(650) 723-7621 (phone) (650) 725-9113 (fax)
Stanford Medicine Hematology Oncology
265 Campus Dr STE G2120B, Stanford, CA 94305
(650) 498-6000 (phone) (650) 724-1231 (fax)
Education:
Medical School
Stanford University School of Medicine
Graduated: 2003
Conditions:
Non-Hodgkin's Lymphoma, Peripheral Nerve Disorders, Ventral Hernia
Languages:
English
Description:
Dr. Alizadeh graduated from the Stanford University School of Medicine in 2003. He works in Palo Alto, CA and 1 other location and specializes in Hematology/Oncology. Dr. Alizadeh is affiliated with Stanford Hospital.
Arash Alizadeh Photo 2

Arash Ash Alizadeh, Palo Alto CA

Specialties:
Internal Medicine
Hematology
Medical Oncology
Hematology & Oncology
Work:
Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304Stanford University
875 Blake Wilbur Dr, Stanford, CA 94305
Education:
Stanford University (2003)
Arash Alizadeh Photo 3

Arash Ash Alizadeh, Stanford CA

Specialties:
Internist
Address:
269 Campus Dr, Stanford, CA 94305
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)

Resumes and CV

Resumes

Arash Alizadeh Photo 4

Arash Alizadeh

Education:
Università Iuav Di Venezia 2011 - 2017
Arash Alizadeh Photo 5

Arash Alizadeh

Business & Organization Records

Name / TitleCompany / ClassificationPhones & Addresses
Arash Ash Alizadeh Arash Alizadeh MD,PHD 875 Blake Wilbur Dr, Stanford, CA 94305
(650) 496-6000

Publications

Us Patents

Synergistic Anti-Cd47 Therapy For Hematologic Cancers

US Patent:
2012028, Nov 8, 2012
Filed:
Sep 15, 2010
Appl. No.:
13/394060
Inventors:
Irving L. Weissman - Stanford CA, US
Ravindra Majeti - Stanford CA, US
Arash Ash Alizadeh - San Mateo CA, US
Mark P. Chao - Mountain View CA, US
International Classification:
A61K 39/395
A61K 51/10
C07K 16/30
A61P 35/00
A61P 35/02
US Classification:
424 149, 4241741, 5303873, 4241781
Abstract:
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.

Methods For Enhancing Anti-Tumor Antibody Therapy

US Patent:
2012032, Dec 20, 2012
Filed:
Dec 7, 2010
Appl. No.:
13/513523
Inventors:
Holbrook Kohrt - Santa Clara CA, US
Roch Houot - Rennes, FR
Ronald Levy - Stanford CA, US
Arash Ash Alizadeh - San Mateo CA, US
Matthew J. Goldstein - Hillsborough CA, US
James Torchia - Stanford CA, US
International Classification:
A61K 39/395
A61P 35/00
US Classification:
4241741
Abstract:
Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.

Methods Of Prognosis For Non-Hodgkin Lymphoma

US Patent:
2012013, May 31, 2012
Filed:
Oct 5, 2011
Appl. No.:
13/253491
Inventors:
Arash Ash Alizadeh - San Mateo CA, US
Ronald Levy - Stanford CA, US
Andrew J. Gentles - Menlo Park CA, US
Izidore S. Lossos - Miami FL, US
International Classification:
A61K 39/395
A61P 35/00
A61K 31/4375
A61K 31/56
A61K 31/66
A61K 31/704
US Classification:
4241331, 514110, 514 34, 514283, 514179
Abstract:
Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis.

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.